Literature DB >> 32106790

Preliminary Evidence of Pregabalin Misuse among Prescription and/or Illicit Opioid (Mis)users.

Mance E Buttram1, Steven P Kurtz1.   

Abstract

Pregabalin is approved for the management of neuropathic pain, partial-onset seizures, and fibromyalgia. Although it is considered to have low potential for abuse, reports of misuse of pregabalin are emerging. The present study contributes to this literature by presenting preliminary evidence of pregabalin misuse. Mixed method interviews were conducted with prescription and/or illicit opioid (mis)users who reported a history of pregabalin misuse (N = 5). During semi-structured interviews, respondents provided descriptions of this practice, including motivation, route of administration, source, and drugs used/misused in combination with pregabalin. Motivations for pregabalin misuse included the self-treatment of physical pain (N = 1) and to achieve a desired psychoactive effect and/or combat opioid withdrawal symptoms (N = 4). Respondents described the misuse of pregabalin to potentiate the effects of heroin and cocaine, to feel "tipsy," and to experiment. We believe this report represents the first detailed contextual data about the misuse of pregabalin in the U.S. These misuse practices may represent an early indication of a growing problem. The recent permissibility of lower price generic versions has the potential to increase availability, decrease prices, and exacerbate pregabalin misuse.

Entities:  

Keywords:  Pregabalin; opioid; qualitative

Mesh:

Substances:

Year:  2020        PMID: 32106790      PMCID: PMC7282980          DOI: 10.1080/02791072.2020.1734695

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  14 in total

1.  Qualitative Descriptive Methods in Health Science Research.

Authors:  Karen Jiggins Colorafi; Bronwynne Evans
Journal:  HERD       Date:  2016-01-19

Review 2.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

3.  Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2005-07-28

4.  Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).

Authors:  Kirk E Evoy; Jordan R Covvey; Alyssa M Peckham; Leslie Ochs; Kyle E Hultgren
Journal:  Res Social Adm Pharm       Date:  2018-06-28

5.  Pregabalin misuse-related ambulance attendances in Victoria, 2012-2017: characteristics of patients and attendances.

Authors:  Rose Crossin; Debbie Scott; Shalini Arunogiri; Karen Smith; Paul M Dietze; Dan I Lubman
Journal:  Med J Aust       Date:  2018-11-22       Impact factor: 7.738

6.  Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK.

Authors:  Vikas Kapil; Jody L Green; Marie-Claire Le Lait; David M Wood; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

7.  Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings.

Authors:  Rose Cairns; Andrea L Schaffer; Nicole Ryan; Sallie-Anne Pearson; Nicholas A Buckley
Journal:  Addiction       Date:  2018-09-05       Impact factor: 6.526

Review 8.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

9.  An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.

Authors:  Mance E Buttram; Steven P Kurtz; Theodore J Cicero; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-09-13       Impact factor: 4.492

10.  Pregabalin: A range of misuse-related unanswered questions.

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  CNS Neurosci Ther       Date:  2019-03-04       Impact factor: 5.243

View more
  1 in total

1.  Fatalities associated with gabapentinoids in England (2004-2020).

Authors:  Nicola J Kalk; Ching-Ting Chiu; Rasa Sadoughi; Heli Baho; Bryn D Williams; David Taylor; Caroline S Copeland
Journal:  Br J Clin Pharmacol       Date:  2022-04-25       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.